Panel: Hitting the "Reset" Button on Direct-to-CNS Delivery

The expert panel will address the scientific and business challenges and opportunities in this space. Panelists will discuss the difficult nature of providing therapies for diseases of the CNS, covering both device and chemistry-enabled technologies. They will also address questions such as: 

• Can devices take us where chemistry has not?
• What advances being made in the field of chemis conjugation technologies?
• Why is intrathecal, intracerebroventricular and intraparenchymal delivery relevant for CNS and other therapeutic categories?

Finally the panel will talk about lessons learned, particularly with regard to scientific vs. business rationale.

Introduction by:

PJ Anand

Founder President and CEO, Lifesciences

Moderator: Lisa Shafer, PhD

Senior Director New Devices and Bioelectronic Technologies Teva Pharmaceuticals

Panelists: Dan Abrams, MD

CEO, Cerebral Therapeutics, LLC 

Krystof Bankiewicz, MD, PhD

Director, Interventional Neuro Center UCSF

Mikhail "Misha" Papisov, PhD

Associate Professor Harvard Medical School and Massachusetts General Hospital

Lamya Shihabuddin, PhD

R&D Cluster Head Neuro Rare Diseases, Sanofi R&D  

This Discussion took place on Day 2 of the Partnership Opportunities in Drug Delivery (PODD) 2017 Meeting.